Skip to main content
. 2021 Dec 18;13(24):6365. doi: 10.3390/cancers13246365

Figure 3.

Figure 3

Targeting of TIM-3 with monoclonal antibodies (mAbs), oligonucleotides (such as nuclease-resistant 2’-fluoropyrimidine RNA aptamers [69]), peptides (12-mer P26 [71]) and small heterocyclic molecules (natural products and synthetic compounds).